Stock fact sheet · data as of
Interpace Biosciences, Inc. (IDXG): fair value, margin of safety and Wheel Score
Healthcare · Medical - Diagnostics & Research · United States · Value
Is IDXG undervalued?
At 5.27 (close of 16 Oct 2026), IDXG trades 95% below the GLS average fair value of 105.34. That average comes from 7 models run on the latest filings, and 7 of them land above the current price. Margins of safety over 30% are the exception rather than the rule across the ~7,400 stocks we value each night, so the number earns Interpace Biosciences, Inc. the full Value points in the Wheel Score - and a closer look at what the market is pricing in.
The 7 models disagree widely: DCF gives 5.75 while GLS Growth gives 270.14. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files IDXG under Value: positive earnings at a P/E of 18 or less.
Nine valuation models for IDXG
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 5.75 | +9% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 20.41 | +287% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 252.40 | +4689% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 110.32 | +1993% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 270.14 | +5026% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | 29.33 | +457% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 49.03 | +830% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -0.2669 | -105% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is average - IDXG passes 5 of the nine Piotroski tests, which falls one point short of the Sunday Scan's "6 or more" rule. The Financials tab on the Quote page shows which tests fail. The GLS Moat score is low at 4.4 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are high - ROIC 104.4%, ROE 109.9%, ROA 72.6% - with debt at 0.05 times equity and a free-cash-flow yield of 13.2%.
Interpace Biosciences, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Reportable 100% (fiscal year FY2025).
Institutional ownership scores 5/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 5 / 9 | ROIC | 104.4% |
|---|---|---|---|
| GLS Moat | 4.4 / 10 | ROE | 109.9% |
| Debt / equity | 0.05 | ROA | 72.6% |
| Free-cash-flow yield | 13.2% | Payout ratio | 0% |
| Institutions | 5 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 39: No options
IDXG has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (39 here). The valuation and quality numbers still apply to owning the shares outright.
Volume runs at 2k shares a day on a market cap of $31M, with a beta of 0.60 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 95% margin of safety | |
| Health | 11 / 20 | Piotroski 5/9 | |
| Moat | 7 / 15 | moat 4.4/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 6 / 20 | 2k shares/day, $31M cap, beta 0.60 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 11 Nov 2026, 26 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Diagnostics & Research
The 12 companies below are the closest to Interpace Biosciences, Inc. by market cap within the Medical - Diagnostics & Research industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| BIOQ Bioqual, Inc. | 33.00 | 21.90 | -51% | 18No options | $30M |
| BIAF bioAffinity Technologies, Inc. | 3.96 | - | - | 28No options | $25M |
| PRPO Precipio, Inc. | 22.25 | 9.87 | -125% | 21No options | $40M |
| QUCY Quantum Cyber N.V. | 1.03 | - | - | 28No options | $23M |
| BNR Burning Rock Biotech Limited | 15.60 | - | - | 30No options | $17M |
| MDXH MDxHealth S.A. | 0.6036 | - | - | 35No options | $58M |
| LDDD Longduoduo Company Limited | 0.5100 | - | - | 23No options | $15M |
| IMDX Insight Molecular Diagnostics Inc. | 3.06 | - | - | 28Weak | $100M |
| ADVB Advanced Biomed Inc. Common Stock | 4.88 | 3.31 | -48% | 17No options | $8M |
| NDRA ENDRA Life Sciences Inc. | 5.10 | - | - | 26No options | $8M |
| BDSX Biodesix, Inc. | 24.71 | - | - | 30No options | $201M |
| XGN Exagen Inc. | 8.42 | - | - | 43Weak | $204M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about IDXG
Is IDXG undervalued right now?
By the GLS models, yes: at 5.27 the stock is 95% below the average fair value of 105.34 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of IDXG and what does it mean?
IDXG has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for IDXG?
105.34 per share as of 16 Oct 2026 - the simple average of the 7 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Interpace Biosciences, Inc. report earnings next?
The next earnings report is due on 11 Nov 2026, 26 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does IDXG have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on IDXG, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.